Core Viewpoint - The company ADMA Biologics refutes allegations made by short seller Culper Research regarding its immune globulin product ASCENIV, emphasizing that demand and utilization have steadily increased over the past two years, reaching record levels [1][2]. Group 1: Demand and Utilization - Demand for ASCENIV has shown significant growth, with data from distribution partners indicating an increase in end-user demand over the past two-plus years [5]. - As of January 5, 2026, and March 22, 2026, average inventory days on hand for ASCENIV were reported at 84 and 48 days, respectively, exceeding the distributors' minimum requirements [7]. - The company maintains that its distributors stock above the minimum levels to ensure continuity of care for immune-compromised patients who require therapy every 21-28 days [6]. Group 2: Inventory Management - Inventory levels for ASCENIV and BIVIGAM are consistent with industry standards, with average days of inventory on hand reported at 128 and 90 days for ASCENIV as of January 5, 2026, and March 22, 2026, respectively [10]. - The company asserts that these inventory levels are appropriately sized to ensure proper handling and mitigate potential supply chain disruptions [10]. Group 3: Competitive Positioning - ASCENIV is positioned as a late-line therapy for immune-compromised individuals who do not respond to standard immunoglobulin treatments, allowing it to command premium pricing [15]. - The short report's claims regarding competitive pressure from new immune globulin product launches are described as misguided by the company [15][13]. Group 4: Financial Integrity - ADMA has received unqualified opinions in its audits for FY 2024 and FY 2025, confirming the effectiveness of its internal controls over financial reporting [14]. - The company has filed its Annual Reports on Form 10-K for the years ended December 31, 2024, and 2025, with no undisclosed related party transactions reported [15].

Core Viewpoint - ADMA Biologics, Inc. has responded to a negative report by Culper Research, which holds a short position in the company, asserting that the report is based on speculative and unreliable sources, while ADMA emphasizes its commitment to accurate financial reporting and compliance with regulations [1]. Group 1: Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™ for primary humoral immunodeficiency, BIVIGAM for primary immunodeficiency, and NABI-HB for hepatitis B immunity [2]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, and operates an FDA-licensed plasma fractionation facility in Boca Raton, Florida [2]. Group 2: Regulatory Compliance and Response - ADMA's Board of Directors is committed to fair and accurate reporting of its financial results and adheres to U.S. Securities and Exchange Commission regulations and U.S. GAAP standards [1]. - The company is taking steps to review the assertions made in the Short Report, which it claims contains numerous misleading and inaccurate statements [1].

Core Viewpoint - Arbor Realty Trust (NYSE:ABR) is experiencing a significant conflict between aggressive insider buying and a strong short-seller position, indicating differing perspectives on the company's financial health and future prospects [2][6]. Short-Seller Position - Approximately 47.24 million shares are sold short, accounting for 29.09% of the float, with a short interest increase of 3.56% since the last report [3]. - The company has 26 non-performing loans with an unpaid principal balance of $569.1 million, and a charge-off of $68.90 million in Q4 2025 related to legacy loans [3]. - Net income decreased to $14.57 million in Q4 2025 from $59.83 million in Q4 2024, raising concerns about financial stability [3]. - The quarterly dividend of $0.30 exceeds the distributable earnings of $0.19 per share for Q4, which raises additional red flags [3]. Analyst Sentiment - Analysts have revised the Zacks consensus estimate down by 28.1% over the last 30 days, resulting in a Zacks Rank of 4 (Sell) for the stock [4]. - CEO Ivan Kaufman noted that ICE enforcement activity in Sun Belt markets has led to significant drops in occupancy rates at affected properties, particularly in Houston [4]. Insider Counter-Argument - CEO Ivan Kaufman and the management team have been actively purchasing shares, with Kaufman buying 210,000 shares in May 2025 and an additional 29,000 shares in November 2025 [5]. - The company repurchased $20.0 million of its stock, and institutional investor Azora Capital added 646,728 shares in March 2026, indicating confidence from insiders [6]. - Arbor's dividend yield stands at 15.6%, significantly higher than the 4.23% yield of the 10-year Treasury, contingent on resolving the $569.1 million in non-performing loans and achieving projected fiscal year EPS of $1.10 [6].

Core Viewpoint - SoFi Technologies (SOFI) is facing scrutiny from short seller Muddy Waters, which has issued a report questioning the company's growth and financial practices. However, SoFi's CEO has made a significant stock purchase, and the company is considering legal action against the report's claims [1][2][3]. Group 1: Stock Performance and Insider Activity - SOFI stock rose over 1% in pre-market trading after a decline of about 1.5% due to the Muddy Waters report [1]. - CEO Anthony Noto purchased 29,800 shares at an average price of $17.32, totaling over $500,000, indicating confidence in the company's future [1]. - In the last three months, SoFi received a "Very Positive" score based on insider buys worth $1.2 million [1]. Group 2: Response to Muddy Waters' Report - SoFi disputes the claims made by Muddy Waters, stating they reflect a fundamental misunderstanding of the company's financials [2]. - The company accuses Muddy Waters of creating a report designed to deceive investors for profit [3]. - SoFi emphasizes its adherence to U.S. GAAP and SEC regulations, asserting the integrity of its financial reporting [4]. Group 3: Analyst Sentiment and Valuation - Despite solid financials and member growth, analysts express caution regarding SOFI stock due to valuation concerns [5]. - Wall Street has a Hold consensus rating on SOFI, with seven Holds, five Buys, and three Sells [5]. - The average price target for SOFI is $25.96, suggesting a potential upside of 49.5% [5].

Group 1 - The tech sector has experienced a significant downturn in 2026, particularly affecting software stocks, resulting in a $24 billion gain for short-sellers [1][2] - Short-sellers have profited substantially over the last six weeks, with a report indicating billions in paper profits as they anticipated a decline in tech stocks [2] - U.S. software stocks have generated $24 billion in mark-to-market profit and loss (MTM PNL) for short-sellers year-to-date, while the sector's market capitalization has decreased by $1 trillion [3] Group 2 - S3 Partners highlighted that short-sellers have been increasingly betting against major software stocks, with Microsoft being a notable example due to changing short-seller behavior amid its decline [5][6] - Historically, Microsoft has shown a tendency for short-covering during downturns, but it is currently behaving like a distressed stock with increasing short positions [6] - Hedge funds are focusing on increasing short positions in large-cap tech stocks, with notable increases in short interest for AVGO and AMZN, which have seen declines of 10% and 15% respectively year-to-date [7]

Core Viewpoint - Hedge funds are significantly increasing their short positions against software stocks, leading to a substantial decline in the sector, with a total market value loss of $1 trillion this year [1][3]. Group 1: Hedge Fund Activity - Hedge funds have realized a $24 billion profit from shorting software stocks in 2026 [1]. - Analysts indicate that hedge funds are currently net short on software stocks, reflecting a bearish sentiment in the industry [4]. Group 2: Market Performance - The iShares Expanded Tech-Software ETF (IGV) has experienced an 8% drop this week, contributing to a year-to-date loss exceeding 21% [3]. - Since reaching its all-time high in September of the previous year, the ETF has declined by 30% [3]. Group 3: Focus of Short Selling - The primary targets for short selling are companies offering basic automation services that can be easily replicated by emerging AI technologies [2].

Group 1: Michael Burry's Investment Strategies - Michael Burry gained fame for shorting the housing market and subprime mortgages, leading to significant profits during the 2008 financial crisis [2][3] - He has a history of making successful predictions, including shorting overvalued tech stocks before the dot-com bubble burst in 2000 and warning about meme stocks and crypto leverage in 2021 [5][6] - Burry recently closed his hedge fund, Scion Asset Management, citing a disconnect between his valuation estimates and market prices [6] Group 2: GameStop Investment - Burry disclosed his recent purchases of GameStop Corp. (NYSE: GME), a video game retailer that gained viral attention in early 2021 due to retail investors on Reddit's r/WallStreetBets [8] - The stock price of GameStop surged from less than $20 to nearly $500 within a few days due to significant buying pressure [9] - Burry expressed his expectation of buying GameStop shares at what may soon be 1x tangible book value / 1x net asset value [10]

Core Insights - ImmunityBio's share price has surged significantly, tripling in value over three weeks, leading to increased trading volume and interest from short-sellers [2][4]. Company Overview - ImmunityBio specializes in developing immunotherapies for cancers and infectious diseases, with a current market capitalization of $6.4 billion [2]. - The stock closed at $6.92, reflecting a 6.79% increase on the day, with a trading volume of 96 million shares, which is approximately 357% above its three-month average [2]. Market Context - The S&P 500 and Nasdaq Composite also saw gains, with increases of 1.16% and 1.18% respectively, indicating a positive market environment for biotechnology stocks [3]. - Other biotechnology peers, such as Nkarta and Allogene Therapeutics, also experienced stock price increases, highlighting ongoing investor interest in higher-risk drug developers [3]. Short-Selling Dynamics - Short-sellers are facing significant losses, with nearly $500 million in paper losses reported due to 35% of ImmunityBio's public float being held short prior to the stock's recent rise [5]. - The recent price increase is attributed to short-sellers potentially covering their positions following a series of positive developments for the company [4].

Core Viewpoint - The company reaffirms its financial strength and strategic progress despite elevated short-selling activity, emphasizing a significant disconnect between its market valuation and intrinsic value [1][2][3]. Financial Position - Total assets exceed US$106.7 million, with cash, cash equivalents, and short-term investments totaling approximately US$53.8 million, and shareholders' equity at around US$56.9 million [3]. - The current market capitalization is approximately US$14 million, representing about 25% of net asset value and less than 30% of cash and short-term investments [3]. Expense Management - Increased operating expenses are attributed to a prolonged shareholder control dispute, which is exceptional and non-recurring, not indicative of operational weakness [4]. - The company has optimized its cost structure and improved the efficiency of strategic capital deployment while maintaining stable operational progress [4]. Income Generation - The company generated over US$3.5 million in interest and investment income during the first nine months, showcasing a resilient financial foundation [5]. Strategic Focus - The company aims to expand higher-margin experiential and live entertainment businesses, advance monetization models, and pursue selective investment opportunities [6]. - With liquidity exceeding US$53 million, the company is positioned to execute its growth strategy without pressure from short-term market fluctuations [6]. Shareholder Guidance - The company advises shareholders to exercise caution regarding unverified commentary and to evaluate based on official disclosures and long-term value rather than short-term price movements [7]. - Management remains confident in delivering sustainable value to long-term shareholders and is committed to transparent communication and disciplined execution [8].

Core Viewpoint - The US Securities and Exchange Commission (SEC) has delayed the compliance deadlines for hedge funds and large investors regarding new disclosure rules for short selling and stock lending, extending the deadlines to January 2, 2028, and September 28, 2028, respectively [1][2]. Group 1: SEC Actions and Regulations - The SEC's decision to delay compliance is characterized as necessary for public interest and investor protection [1]. - The new rules, issued in October 2023, require certain investment managers to report short-sale data monthly, with pension funds, banks, and institutional money managers required to report stock lending transactions the following day [2]. Group 2: Industry Reactions - Trade groups such as the Managed Funds Association and the Alternative Investment Management Association have legally challenged the SEC's rules, arguing they exceed the agency's authority and lack consideration of economic impacts [3]. - AIMA expressed satisfaction with the delay, viewing it as a relief for market participants while the SEC reassesses its approach [4]. Group 3: Internal SEC Perspectives - SEC Commissioner Caroline Crenshaw has voiced concerns regarding the delay, labeling it as a potential indefinite postponement of compliance and suggesting it undermines the rule of law [5][6].